Caricamento azienda
Just reported
From Phathom Pharmaceuticals's results release of 29 ottobre 2026; its quarterly report has since been filed.
Actual
84,7M USD
+71% y/y
+14% q/q
Guided
—
No guide given
Actual
-0,16 USD
Guided
—
No guide given
Actual
-85K USD
Guided
—
No guide given
Full year 2026
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The themes Phathom Pharmaceuticals is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
ONCBeone Medicines Ltd.47,6B USDA+
EXELExelixis, Inc.16,8B USDA+
JAZZJazz Pharmaceuticals plc15,5B USDA
TECHBIO-Techne Corp11,4B USDA+
HALOHalozyme Therapeutics, Inc.11,4B USDA+Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 ott 2026CBGraded C, now B
MCKMckesson Corporation4 nov 2026BAGraded B, now A
CVSCVS Health Corp4 nov 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 nov 2026BAGraded B, now A
GEHCGE Healthcare Technologies Inc.28 ott 2026CAGraded C, now ACostruito dai documenti depositati da Phathom Pharmaceuticals, Inc. presso la Securities and Exchange Commission (SEC), l’autorità di vigilanza statunitense. Le cifre sono quelle dichiarate, con lo storico per azione ricalcolato sulla base azionaria di oggi. Questo descrive un’azienda: non è consulenza finanziaria né una raccomandazione di acquisto o vendita.
Previsione dell’azienda: ricavi di da 310M USD a 325M USD per Esercizio 2026 — in crescita del 81,3% sull'anno precedente
Grade B
La fascia sotto il prezzo mostra il voto in ogni data, calcolato solo sui documenti già pubblici in quel momento.
Mostra 2 trimestri su 12 dello storico dei voti di Phathom Pharmaceuticals, Inc.. Gli altri 10 risalgono fino a marzo 2024.
